Economic evaluation of smoking-cessation therapies: A critical and systematic review of simulation models

PharmacoEconomics

Volumn 30, Issue 7, 2012, Pages 551-564

  Bolin, Kristian ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Cost effectiveness; Modelling; Smoking cessation therapies.

Indexed keywords

COST EFFECTIVENESS ANALYSIS; DRUG USE; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; OBESITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; RELIABILITY; REVIEW; RISK REDUCTION; SMOKING CESSATION; SMOKING CESSATION PROGRAM; SYSTEMATIC REVIEW;

COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; HUMANS; MARKOV CHAINS; MODELS, ECONOMIC; MODELS, STATISTICAL; QUALITY-ADJUSTED LIFE YEARS; SMOKING CESSATION;

EID: 84862219638     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11590120-000000000-00000     Document Type: Review

References (65)

1. Wynder EL, Graham EA. Tobacco smoking as a possible etiologic factor in bronchiogenic carcinoma: A study of 684 proved cases. JAMA 1950; 143:329-96
2. Doll R, Hill AB. The mortality of doctors in relation to their smoking habits: A preliminary report. BMJ 1954; 1:1451-5
3. Doll R, Hill AB. Lung cancer and other causes of death in relation to smoking: A second report on the mortality of British doctors. BMJ 1956; 2:1071-81
4. Hammond ED, Horn D. Smoking and death rates - report on forty-four months of follow-up on 187,783 men:I. Total mortality. JAMA 1958; 166:1159-72
5. Hammond ED, Horn D. Smoking and death rates - report on forty-four months of follow-up on 187,783 men:II. Death rates by cause. JAMA 1958; 166:1294-308
6. Royal College of Physicians. Smoking and health:summary and report of the Royal College of Physicians of London on smoking in relation to cancer of the lung and other diseases. New York:Pitman Publishing, 1962
7. World Health Organization. Tobacco or health: A global status report. Geneva:WHO, 1997
8. Fagerström K. The epidemiology of smoking:health consequences and benefits of cessation. Drugs 2002; 62 Suppl. 2:1-9 (Pubitemid 34809710)
9. Shafey O, Dolwick S, Guindon GE, editors. Tobacco control country profiles. 2nd rev. ed. Atlanta (GA):American Cancer Society, 2003
10. Abrams DB, Graham AL, Levy DT, et al. Boosting population quits through evidence-based cessation treatment and policy. Am J PrevMed 2010Mar; 38 (3 Suppl.):S351-63
11. Hughes JR. How confident should we be that smoking cessation treatments work? Addiction 2009; 104 (10):1637-40
12. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking- Attributable deaths:confounding in the courtroom. JAMA 2000; 284:706-12 (Pubitemid 30646339)
13. Woolacott NF, Jones L, Forbes CA, et al. The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: A systematic review and economic evaluation. Health Technol Assess 2002; 6 (16):1-245
14. Keating GM, Lyseng-Williamson KA. Varenicline: A pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics 2010; 28 (3):231-54
15. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic evaluation of health technologies. Health Econ 2006; 15 (12):1295-310 (Pubitemid 44941606)
16. Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision- Analytic modelling in health technology assessment: A review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4):355-71
17. Elixhauser A. The costs of smoking and the cost effectiveness of smoking-cessation programs. J Public Health Policy 1990; 11 (2):218-37 (Pubitemid 20361551)
18. Song F, Raftery J, Aveyard P, et al. Cost-effectiveness of pharmacological interventions for smoking cessation: A literature review and a decision analytic analysis. Med Decis Making 2002; 22 (5 Suppl.):S26-37
19. Ronckers ET, Groot W, Ament AJ. Systematic review of economic evaluations of smoking cessation:standardizing the cost-effectiveness. Med Decis Making 2005; 25 (4):437-48 (Pubitemid 41023171)
20. Orme ME, Susan LH, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001; 10:55-6
21. Gunning-Schepers LJ. The health benefits of prevention: A simulation approach. Health Policy 1989; 12:1-256
22. Wetter D, Cofta-Gunn L, Fouladi R, et al. Late relapse/ sustained abstinence among former smokers: A longitudinal study. Prev Med 2004; 39:1556-63
23. Krall E, Garvey A, Garcia R. Smoking relapse after 2 years of abstinence:findings from the VA Normative Aging Study. Nicotine Tob Res 2002; 4:95-100 (Pubitemid 34521101)
24. Hoogenveen RT, de Hollander AEM, van Genugten MLL. The chronic disease modeling approach. Bilthoven:National Institute of Public Health and the Environment (RIVM), 1998
25. Brønnum-Hansen H. How good is the Prevent model for estimating the health benefits of prevention? J Epidemiol Community Health 1999; 53 (5):300-5 (Pubitemid 29187115)
26. Prevent [computer program]. Version 3.01. Wilston (QLD):EpiGear International, 2009 [online]. Available from URL:http://www.epigear.com/index- files/prevent.html [Accessed 2011 Feb 5]
27. Hoogenveen RT, van Baal PHM, Boshuizen HC. Chronic disease projections in heterogeneous ageing populations: Approximating multi-state models of joint distributions by modeling marginal distributions. Math Med Biol 2010; 27:1-19
28. Hurley SF, Matthews JP. The Quit Benefits Model: A Markov model for assessing the health benefits and health care cost savings of quitting smoking. Cost Eff Resour Alloc 2007; 5:2-20
29. Tengs TO, Ahmad S, Savage JM, et al. The AMA proposal to mandate nicotine reduction in cigarettes: A simulation of the population health impacts. Prev Med 2005; 40:170-80 (Pubitemid 39468607)
30. Tengs T, Ahmad S, Moore R, et al. Federal policy mandating safer cigarettes: A hypothetical simulation of the anticipated population health gains or losses. J Policy Anal Manage 2004; 3:857-72 (Pubitemid 39332670)
31. Igarashi A, Takuma H, Fukuda T, et al. Cost-utility analysis of varenicline, an oral smoking-cessation drug, in Japan. Pharmacoeconomics 2009; 27 (3):247-61
32. Thavorn K, Chaiyakunapruk N. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand. Tob Control 2008; 17 (3):177-82
33. Dino G, Horn K, Abdulkadri A, et al. Cost-effectiveness analysis of the Not On Tobacco program for adolescent smoking cessation. Prev Sci 2008; 9 (1):38-46
34. Welton NJ, Johnstone EC, David SP, et al. A costeffectiveness analysis of genetic testing of the DRD2 Taq1A polymorphism to aid treatment choice for smoking cessation. Nicotine Tob Res 2008; 10 (1):231-40
35. Hurley SF, Matthews JP, Guymer RH. Cost-effectiveness of smoking cessation to prevent age-related macular degeneration. Cost Eff Resour Alloc 2008; 6:18
36. Bertram MY, Lim SS, Wallace AL, et al. Costs and benefits of smoking cessation aids:making a case for public reimbursement of nicotine replacement therapy in Australia. Tob Control 2007; 16 (4):255-60
37. Olsen KR, Bilde L, Juhl HH, et al. Cost-effectiveness of the Danish smoking cessation interventions:subgroup analysis based on the Danish Smoking Cessation Database. Eur J Health Econ 2006; 7 (4):255-64
38. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: A multinational comparison. Tob Control 2006; 15 (3):152-9 (Pubitemid 43864869)
39. Cornuz J, Pinget C, Gilbert A, et al. Cost-effectiveness analysis of the first-line therapies for nicotine dependence. Eur J Clin Pharmacol 2003; 59 (3):201-6 (Pubitemid 36995128)
40. Fiscella K, Franks P. Cost-effectiveness of the transdermal nicotine patch as an adjunct to physicians' smoking cessation counseling. JAMA 1996; 275 (16):1247-51 (Pubitemid 26118498)
41. Parrott S, Godfrey C, Raw M, et al. Guidance for commissioners on the cost effectiveness of smoking cessation interventions:health educational authority. Thorax 1998; 53 Suppl. 5:1-38
42. Ratcliffe J, Cairns J, Platt S. Cost effectiveness of a mass media-led anti-smoking campaign in Scotland. Tob Control 1997; 6 (2):104-10 (Pubitemid 127685514)
43. Vemer P, Rutten-van Mölken M, Kaper J, et al. If you try to stop smoking, should we pay for it? The cost-utility of reimbursing smoking cessation support in the Netherlands. Addiction 2010; 105 (6):1088-97
44. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation interventions: A dynamic modeling study. Value Health 2005; 8 (3):178-90 (Pubitemid 41023477)
45. Hurley SF, Matthews JP. Cost-effectiveness of the Australian National Tobacco Campaign. Tob Control 2008; 17 (6):379-84
46. Bae JY, Kim CH, Lee EK. Evaluation of cost-utility of varenicline compared with existing smoking cessation therapies in South Korea. Value Health 2009; 12 Suppl. 3:S70-3
47. Bolin K, Mö rk AC, Wilson K. Smoking-cessation therapy using varenicline: The cost-utility of an additional 12-week course of varenicline for the maintenance of smoking abstinence. J Eval Clin Pract 2009; 15 (3):478-85
48. Bolin K, Mö rk AC, Willers S, et al. Varenicline as compared to bupropion in smoking cessation therapy:cost-utility results for Sweden. Respir Med 2008; 102 (5):699-710
49. Bolin K, Lindgren B, Willers S. The cost utility of bupropion in smoking cessation health programs:simulation model results for Sweden. Chest 2006; 129 (3):651-60
50. Johansson PM, Tillgren PE, Guldbrandsson KA, et al. A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit- And-Win contest for mothers of small children. Scand J Public Health 2005; 33 (5):343-52 (Pubitemid 41582345)
51. Halpern MT, Khan ZM, Young TL, et al. Economic model of sustained-release bupropion hydrochloride in health plan and work site smoking-cessation programs. Am J Health Syst Pharm 2000; 57 (15):1421-9 (Pubitemid 30620432)
52. Heitjan DF, Asch DA, Ray R, et al. Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment. Pharmacogenomics J 2008; 8 (6):391-9
53. Bolin K, Wilson K, Benhaddi H, et al. Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation:results from four European countries. Eur J Public Health 2009; 19 (6):650-4
54. Vemer P, Rutten-van Mö lken M. Crossing borders:factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries. Value Health 2010; 13 (2):230-41
55. Knight C, Howard P, Baker CL, et al. The cost-effectiveness of an extended course (12+12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: An extension and update to the BENESCO Model. Value Health 2010; 13 (2):209-14
56. Linden K, Jormanainen V, Linna M, et al. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers. Curr Med Res Opin 2010; 26 (3):549-60
57. Annemans L, Nackaerts K, Bartsch P, et al. Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation. Clin Drug Investig 2009; 29 (10):655-65
58. Hoogendoorn M, Welsing P, Rutten-van Mö lken MP. Costeffectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands. Curr Med Res Opin 2008; 24 (1):51-61 (Pubitemid 351160238)
59. Tengs TO, Osgood ND, Chen LL. The cost-effectiveness of intensive national school-based anti-tobacco education:results from the Tobacco Policy Model. Prev Med 2001; 33:558-70 (Pubitemid 34101879)
60. Meltzer D. Accounting for future costs in medical costeffectiveness analysis. J Health Econ 1997; 16:33-64 (Pubitemid 27224093)
61. Lundin D, Ramsberg J. On survival consumption costs: A reply to Nyman. Health Econ 2008; 17 (2) 293-7 (Pubitemid 351266001)
62. Nyman JA. Should the consumption of survivors be included as a cost in cost-utility analysis? Health Econ 2004; 13:417-27 (Pubitemid 38660391)
63. Nyman JA. More on survival consumption costs in costutility analysis. Health Econ 2006; 15:319-22 (Pubitemid 43349354)
64. Howard P, Knight C, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: Application to a population of US adult smokers. Pharmacoeconomics 2008; 26 (6):497-511 (Pubitemid 351704858)
65. Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford:Oxford University Press, 2006